NCT07006974 is a clinical trial of SMCs in Syndromic and Metabolic Cardiomyopathy, sponsored by China National Center for Cardiovascular Diseases.

Who is sponsoring NCT07006974?

NCT07006974 is sponsored by China National Center for Cardiovascular Diseases.

What drugs are being tested in NCT07006974?

Interventions in NCT07006974: SMCs.

What condition does NCT07006974 study?

NCT07006974 studies Syndromic and Metabolic Cardiomyopathy, Cardiomyopathies.

Is NCT07006974 still recruiting?

NCT07006974 is currently active, enrolled. Last updated 8 January 2026.

Last reviewed 2026-01-08 · How we verify

NCT07006974

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SMCs With LVH Compared to HCM

Active, enrolled Last updated 8 January 2026

What this trial tests

trial testing SMCs in Syndromic and Metabolic Cardiomyopathy in 165 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 May 2025

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	China National Center for Cardiovascular Diseases
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	165
Start date	27 May 2025
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

SMCs

Conditions studied

Syndromic and Metabolic Cardiomyopathy — all drugs for Syndromic and Metabolic Cardiomyopathy →
Cardiomyopathies — all drugs for Cardiomyopathies →

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

Eligibility, any sex, with Syndromic and Metabolic Cardiomyopathy or Cardiomyopathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this cohort study is to investigate the clinical characteristics of SMCs and to explore the difference in cardiovascular outcomes in comparison to age-, sex-, and admission year-matched HCM patients. The main question it aims to answer is: * Do patients with SMCs have higher rates of cardiac outcomes? * What risk factors do SMCs patients experience a poor prognosis?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

NCT07514988 — Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment · NA · not yet recruiting
NCT07476456 — Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death · not yet recruiting
NCT07302659 — Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG · NA · recruiting
NCT07482683 — Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach · not yet recruiting
NCT06787430 — Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07006974 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China National Center for Cardiovascular Diseases
Last refreshed: 8 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07006974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing